Is common genetic variation at IRS1, ENPP1 and TRIB3 loci associated with cardiometabolic phenotypes in type 2 diabetes? An exploratory analysis of the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 5

2016 ◽  
Vol 26 (3) ◽  
pp. 232-238 ◽  
Author(s):  
M. Trombetta ◽  
M. Dauriz ◽  
S. Bonetti ◽  
D. Travia ◽  
L. Boselli ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Genetic Variation ◽  
Exploratory Analysis ◽  
Newly Diagnosed ◽  
Common Genetic Variation

scholarly journals Contribution of Common Genetic Variation to the Risk of Type 2 Diabetes in the Mexican Mestizo Population

Diabetes ◽  
2012 ◽  
Vol 61 (12) ◽  
pp. 3314-3321 ◽  
Author(s):  
M. A. Gamboa-Melendez ◽  
A. Huerta-Chagoya ◽  
H. Moreno-Macias ◽  
P. Vazquez-Cardenas ◽  
M. L. Ordonez-Sanchez ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Genetic Variation ◽  
Common Genetic Variation ◽  
Mexican Mestizo ◽  
Mexican Mestizo Population

scholarly journals Association between Three Variants in the PRKAA2 gene, rs2796498, rs9803799, and rs2746342, with 10-year ASCVD Risk on Newly Diagnosed T2DM in Yogyakarta, Indonesia

2021 ◽  
Vol 9 (A) ◽  
pp. 541-547
Author(s):  
Dita Maria Virginia ◽  
Mae Sri Hartati Wahyuningsih ◽  
Dwi Aris Agung Nugrahaningsih
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Genetic Variation ◽  
High Risk ◽  
Hba1c Level ◽  
Genetic Factors ◽  
Newly Diagnosed ◽  
Glucose And Lipid Metabolism ◽  
Ascvd Risk

BACKGROUND: AMPK has pivotal roles in glucose and lipid metabolism, including  AMPKa2, which PRKAA2 encodes. Metformin as an anti-hyperglycemia agent acts through AMPK. Poor glycemia control among patients with type 2 diabetes mellitus (T2DM) could increase atherosclerosis cardiovascular disease (ASCVD) risk. Therefore, PRKAA2 genetic variation might contribute to 10-year ASCVD risk in patients with newly diagnosed T2DM receiving monotherapy metformin. AIM: The study aimed to detect an association between PRKAA2 genetic variation with 10 year-ASCVD risk among newly diagnosed T2DM patients prescribed monotherapy metformin. METHODS: This present study was a case-control study involving 107 participants. Analysis of PRKAA2 genetic variation was performed using the TaqMan assay. RESULTS: A total of 91 participants who fulfilled our criteria enrolled in this study. Most of the participants were female, with mean age 54.40±7.75 years old, mean HbA1c level of 8.35±1.31%, and the lipid profile indicated normal conditions. There was a significant difference in age (p<0.01), HbA1c level (p=0.04), sex (p<0.01), and smoking status (p<0.01) between low-risk and high-risk groups. The GT genotype of rs9803799 had 187.86 times higher possibility for high-risk of 10-year ASCVD risk than TT genotype (OR=187.86, 95%CI:2.98–11863.51). The dominant model of rs9803799 showed that GT+GG had 94.33 times higher possibility for high-risk of 10-year ASCVD risk than TT genotype (OR=94.33; 95%CI:2.32–3841.21). Other results showed that G allele of rs980377 had 20.48 times higher possibility for high-risk of 10-year ASCVD risk than T allele (OR = 20.48; 95%CI:1.48–283.30). These associations were found after multivariate analysis. CONCLUSION: Our findings indicated that rs9803799 as one of PRKAA2 genetic variations might impact the 10-year ASCVD risk among newly diagnosed T2DM patients receiving monotherapy metformin. After considering non-genetic factors, patient assessment should include potential genetic factors in cases with hyperglycemia involving treatment affecting glucose and lipid metabolism such as monotherapy metformin.   Keywords: PRKAA2, genetic variation, atherosclerosis cardiovascular disease, type 2 diabetes mellitus, metformin, Indonesia

scholarly journals Association of Common Genetic Variation in TheFOXO1Gene with β-Cell Dysfunction, Impaired Glucose Tolerance, And Type 2 Diabetes

2009 ◽  
Vol 23 (2) ◽  
pp. 278-279
Author(s):  
Karsten Müssig ◽  
Harald Staiger ◽  
Fausto Machicao ◽  
Alena Stančáková ◽  
Johanna Kuusisto ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Genetic Variation ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Common Genetic Variation ◽  
Β Cell ◽  
Cell Dysfunction

scholarly journals Common genetic variation in the glucokinase gene (GCK) is associated with type 2 diabetes and rates of carbohydrate oxidation and energy expenditure

Diabetologia ◽  
2014 ◽  
Vol 57 (7) ◽  
pp. 1382-1390 ◽  
Author(s):  
Yunhua L. Muller ◽  
Paolo Piaggi ◽  
Duncan Hoffman ◽  
Ke Huang ◽  
Brittany Gene ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Genetic Variation ◽  
Energy Expenditure ◽  
Carbohydrate Oxidation ◽  
Common Genetic Variation ◽  
Glucokinase Gene

scholarly journals PRKAA2 variation and the clinical characteristics of patients newly diagnosed with type 2 diabetes mellitus in Yogyakarta, Indonesia

2021 ◽  
Vol 15 (4) ◽  
pp. 161-170
Author(s):  
Dita Maria Virginia ◽  
Mae Sri Hartati Wahyuningsih ◽  
Dwi Aris Agung Nugrahaningsih
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Genetic Variation ◽  
Clinical Characteristics ◽  
Genetic Variations ◽  
Clinical Feature ◽  
Newly Diagnosed ◽  
Cross Sectional

Abstract Background Adenosine monophosphate (AMP)-activated protein kinase (AMPK; EC 2.7.11.31) enzymes play a pivotal role in cell metabolism. They are involved in type 2 diabetes mellitus (T2DM) pathogenesis. Genetic variation of PRKAA2 coding for the AMPK α2 catalytic subunit (AMPKα2) is reported to be associated with susceptibility for T2DM. Objectives To determine the association between PRKAA2 genetic variations (rs2796498, rs9803799, and rs2746342) with clinical characteristics in patients newly diagnosed with T2DM. Methods We performed a cross-sectional study including 166 T2DM patients from 10 primary health care centers in Yogyakarta, Indonesia. We measured fasting plasma glucose, hemoglobin A1c, serum creatinine, glomerular filtration rate, blood pressure, and body mass index as clinical characteristics. PRKAA2 genetic variations were determined by TaqMan SNP genotyping assay. Hardy–Weinberg equilibrium was calculated using χ2 tests. Results There was no difference in clinical characteristics for genotypes rs2796498, rs9803799, or rs2746342 (P > 0.05). No significant association was found between PRKAA2 genetic variations and any clinical feature observed. Further subgroup analysis adjusting for age, sex, and waist circumference did not detect any significant association of PRKAA2 genetic variations with clinical characteristics (P > 0.05). Conclusion PRKAA2 genetic variation is not associated with the clinical characteristics of Indonesian patients with newly diagnosed T2DM.

scholarly journals Association of Common Genetic Variation in theFOXO1Gene with β-Cell Dysfunction, Impaired Glucose Tolerance, and Type 2 Diabetes

2009 ◽  
Vol 94 (4) ◽  
pp. 1353-1360 ◽  
Author(s):  
Karsten Müssig ◽  
Harald Staiger ◽  
Fausto Machicao ◽  
Alena Stančáková ◽  
Johanna Kuusisto ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Genetic Variation ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Common Genetic Variation ◽  
Β Cell ◽  
Cell Dysfunction

Metabolic flexibility, insulin sensitivity and genetic variations in newly diagnosed patients with type 2 diabetes

2015 ◽  
Vol 10 (S 01) ◽  
Author(s):  
M Apostolopoulou ◽  
K Strassburger ◽  
B Knebel ◽  
J Kotzka ◽  
J Szendroedi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Sensitivity ◽  
Genetic Variations ◽  
Metabolic Flexibility ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document